Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
RNXT
RNXT
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
RNXT News
RenovoRx Publishes Case Study on Pancreatic Cancer Treatment
4d ago
Newsfilter
RenovoRx CEO to Present at Investment Conference
Jun 04 2026
Newsfilter
RenovoRx Receives FDA Orphan Drug Designation for Oxaliplatin
May 28 2026
NASDAQ.COM
RenovoRx Receives FDA Orphan Drug Designation
May 28 2026
Newsfilter
RenovoRx (RNXT) Q1 2026 Earnings Transcript
May 19 2026
NASDAQ.COM
RenovoRx CEO to Participate in Healthcare Showcase
May 19 2026
Newsfilter
RenovoRx Reports 136% Revenue Growth in Q1 2026
May 15 2026
Yahoo Finance
RenovoRx Q1 Earnings Report Analysis
May 14 2026
seekingalpha
RenovoRx Named 10th Most Innovative Medical Device Company by Fast Company
Apr 01 2026
Newsfilter
RenovoRx Reports Wider Net Loss Despite Revenue Growth in 2025
Mar 31 2026
NASDAQ.COM
RenovoRx Reports Strong 2025 Revenue Growth and Expansion Plans
Mar 31 2026
Yahoo Finance
RenovoRx Reports FY 2025 Financial Results with Private Placement
Mar 30 2026
seekingalpha
RENOVORX REPORTS FY OPERATING EXPENSES OF USD 13.306 MILLION
Mar 30 2026
moomoo
RENOVORX REPORTS FY NET LOSS OF USD 11.168 MILLION
Mar 30 2026
moomoo
Multiple Companies Set to Report Earnings
Mar 30 2026
NASDAQ.COM
RenovoRx TIGeR-PaC Trial Enrollment on Track for 2026 Completion
Mar 26 2026
Newsfilter
Show More News
